Dr. Michael Luther
Dr. Michael Luther is an entrepreneur executive with over 31 years of experience in biopharmaceutical industry. Michael is the CEO of Teewinot Life Sciences, a global leader in the development and production of biosynthetic cannabinoids and their derivatives for consumer and pharmaceutical markets. TLS leverages a unique integrated biocatalytic and chemical platform that today generates an unprecedented range of cannabinoids including NCEs from bench to cGMP manufacturing.
In addition, Mike is the founding CEO of Bantam Pharmaceutical a virtual company with a focus on mitochondrial pathways involved in cancer metabolism where they have a clinical development stage asset.
In prior roles, Michael was the Senior Vice President for Albany Molecular Research (AMRI), where he was responsible for their global discovery and development including the launch of AMRI’s new discovery center in Buffalo. Before AMRI, Mike was the first President of the David H. Murdock Research Institute at the North Carolina Research Campus. Mike spent 19 years in various R&D roles in the global pharmaceutical industry including Vice President and head of R&D for Merck-Canada in Montreal leading Merck’s global discovery efforts in inflammation and metabolic disease, as well multiple roles with GlaxoSmithKline including Vice President in Discovery Research. In these roles, he led multiple discovery teams that led to the successful launch of new therapeutics in oncology and metabolic disease as well as creating some of the pharmaceutical industry’s initial efforts in both precision medicine and drug repositioning. He was a Carl Stone Muscular Dystrophy Fellow at The Salk Institute, and is the author of over 67 publications and holds multiple issued patents in diagnostics and pharmaceuticals.
B.S. Biological Sciences NC State 1978
M.B.A. Fuqua School of Business Duke University 1999
Ph.D. Biochemistry Saint Louis University Medical School 1985